VISTA-GROUP
10.4.2018 18:52:03 CEST | Business Wire | Press release
Vista Entertainment Solutions (Vista Cinema), the leading provider of cinema management software for the global cinema exhibition market, has completed the rollout for its first customer in Italy, The Space Cinema, which operates 36 cinemas with 362 screens. The Space Cinema is part of Vue International.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180410006322/en/
Vista Group Chief Executive Kimbal Riley describes the rollout as a fantastic achievement. “This was a challenging regulatory process in a new territory for Vista and builds on the strong relationship we have with Vue International. It’s a great testament to our excellent local partners that we’ve been able to complete this rollout.”
Managing Director, Europe, Middle East and Africa at Vista Entertainment Solutions, Mischa Kay says: “Together with the fantastic team at The Space Cinema, we have successfully rolled out a broad selection of the Vista Cinema software suite across the Italian circuit. Italy is a top 20 cinema-going market and represents a significant opportunity not only for Vista Cinema, but for the Vista Group as a whole, to provide business benefits to the Italian industry.”
“Vue International continues to implement best practices across its group of circuits in Europe,” says Roland Jones, Executive Director, Technical Services, Vue International. “We are pleased to have extended our relationship with Vista, with whom we have worked extensively in the UK for many years. By introducing Vista’s state-of-the-art, integrated operating system to cinemas such as The Space, we maximize a host of benefits that only the leading global cinema system can deliver.”
The Managing Director of The Space Cinema, Toby Bradon, has also welcomed the completion of the rollout: “On behalf of The Space Cinema, we are very pleased to be the first Italian circuit working with Vista. Following a rapid and successful implementation we look forward to maximising the benefits of Vista’s modern, class-leading cinema operating system. Working in conjunction with our colleagues at Vue International, The Space Cinema continues to invest in its customer experience supporting our mission to be the first choice in cinema entertainment in Italy.”
About The Space Cinema:
The Space Cinema is a leading cinema operator in Italy with 36 multiplex cinemas and 362 screens. Space owns five out of the top ten highest grossing cinemas in Italy including the No.1 grossing cinema in the Italian market - Parco de Medici. The business is a leader in a fragmented cinema market. At the end of 2014, The Space Cinema was acquired by Vue Entertainment International.
About Vue International
Vue International is one of the world's leading cinema operators,
managing the most respected brands in major European markets and Taiwan,
spanning ten countries, 212 sites and 1,902 screens. The group has
leading positions in the United Kingdom, Ireland, Germany, Denmark,
Netherlands, Italy, Poland, Latvia, Lithuania and Taiwan. From its
inception in May 2003 Vue International has grown organically and
through strategic acquisition to deliver a premium out-of-home
entertainment experience by combining the best content, with the best
technology in the best environment.
Website: www.myvue.com/about-us
About Vista Group International:
Vista Group International (Vista Group) is a public company, listed on
both the New Zealand and Australian stock exchanges (NZX & ASX: VGL).
The Group provides software and additional technology solutions across
the global film industry. Cinema management software is provided by
Vista Entertainment Solutions (Vista Cinema), the core business of the
Group. Movio (authority in moviegoer data analytics), Veezi (cloud-based
SaaS software for the Independent Cinema Market), movieXchange
(connecting the movie industry to simplify the promotion and sale of
movie tickets), Maccs (film distribution software), Numero (box office
reporting software for film distributors and cinemas), Cinema
Intelligence (business intelligence solutions), Powster (creative studio
and marketing platform for movie studios) and Flicks (moviegoer ‘go to’
portal for movie information) provide an innovative range of
complementary products across additional film industry sectors, from
production and distribution, to cinema exhibition through to the
moviegoer experience. Vista Group has offices located in New Zealand
(Auckland HQ), Sydney, Los Angeles, London, Shanghai, Beijing, Mexico
City, South Africa, the Netherlands and Romania.
Website: www.vistagroup.co
LinkedIn:
www.linkedin.com/company/vista-group-limited
View source version on businesswire.com: https://www.businesswire.com/news/home/20180410006322/en/
Contact:
Media Contacts:
For Vista Group International/NZ & EUROPE
Christine
Fenby
+64 21 727 006
christine.fenby@vista.co
or
For
Vista Group International/USA
Maggie Begley/MBC
+1 310 390
0101
maggie@mbcprinc.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom